Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Phase 3positiveRemigromigPositive
AI Analysis
Summary
Merck announced that Remigromig, a Wnt pathway tri-specific agonist, met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema in adults. The positive data from this pivotal study represents a significant milestone toward potential regulatory approval.
Clinical Trial Data
Phase
2b/3
Primary Endpoint
Met
Outcome Details
Met primary endpoint in pivotal Phase 2b/3 BRUNELLO trial
Importance:8/10
Sentiment:
0.85
Phase 2b/3Diabetic Macular EdemaWnt PathwayTri-Specific AgonistPivotal TrialPositive Data
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 24, 2026 4:09 AM